- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04918849
WhatsApp in India During the COVID-19 Pandemic
Characterising the Spread of COVID-19 Misinformation Through WhatsApp in India
Digital misinformation has been flagged as a major risk of the 21st century, with an estimated cost of $78 billion to the global economy each year. Given this scope, we propose to characterize how misinformation is spread via messenger platforms (e.g. WhatsApp).
Specifically, we seek to:
- Identify metrics of potential misinformation (Aim 1). This is based on the hypothesis that although message contents are highly private, proxy markers can be used to identify potential misinformation.
- Understand the base-rate by which misinformation is shared via messaging applications (Aim 2). This is founded on the hypothesis that misinformation is endemic on messaging platforms, and thus needs to be documented.
- Identify "super spreaders" responsible for sending and receiving a large volume of misinformation (Aim 3). Here, we hypothesise that a small group of super spreaders are responsible for the bulk of misinformation-sharing on messaging applications.
The thrust of this work aligns with both government priorities and the grant's thematic areas, providing actionable findings that are timely amidst a worldwide surge of misinformation.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jean Liu, PhD
- Phone Number: 66013694
- Email: jeanliu@yale-nus.edu.sg
Study Locations
-
-
-
Singapore, Singapore, 138527
- Recruiting
- Yale-NUS College
-
Contact:
- Jean Liu, PhD
- Phone Number: 66013964
- Email: jeanliu@yale-nus.edu.sg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Lived in India for more than 2 years,
- Currently Living in India
- Owns a WhatsApp account
Exclusion Criteria:
- Not currently living in India
- Below the ages of 21
- Has not lived in India for more than 2 years
- does not own a WhatsApp account
- Does not speak English or Hindi
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
---|
Community Sample
We plan to recruit a community sample of 1000 from the Indian Population.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
WhatsApp Usage
Time Frame: 1 week, starting from date after baseline survey completion
|
Participants were asked a series of questions daily related to their WhatsApp usage behaviors - in particular, their message-forwarding, personal chat and group chat behaviors.
|
1 week, starting from date after baseline survey completion
|
Changes in fear with regards the COVID-19 situation across 1 week
Time Frame: 1 week, starting from date after baseline survey completion
|
1 item each day on fear specifically of the COVID-19 situation (measured on a 4 point scale: min = 1, max = 4; higher scores indicating greater fear about the outbreak).
|
1 week, starting from date after baseline survey completion
|
Changes in amount of thinking about the COVID-19 situation across 1 week
Time Frame: 1 week, starting from date after baseline survey completion
|
1 item each day on how much they thought about the outbreak that day (measured on a 5 point scale: min = 1, max = 5; higher scores indicating more thinking about the outbreak).
|
1 week, starting from date after baseline survey completion
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-CERC-001C
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted